Table 1.
Recent developments of iron oxide nanoparticle-based ARTs nanotherapeutics.
| Nanotherapeutics | ARTs | DLC | Activator | Strategy | Evidence | References | |
|---|---|---|---|---|---|---|---|
| 1 | Fe3O4@C/Ag@mSiO2 | ART | 48.4% | Fe2+/Fe3+ | ART-CDT | in vitro | Chen et al., 2014 |
| 2 | Fe3O4@C@MIL-100(Fe) | DHA | 80.4% | Fe2+/Fe3+ | ART-CDT | in vitro/in vivo | Wang et al., 2016a |
| 3 | Mn3[Co(CN)6]2@MIL-100 (Fe) |
AS | 53.1% | Fe2+/Fe3+ | ART-CDT | in vitro/in vivo | Wang D. et al., 2017 |
| 4 | ART@HQZFNPs | ART | 23.0% | Fe2+/Fe3+ | ART-CDT | in vitro | Pan et al., 2018 |
| 5 | MNP-ART, MNP-DHA, MNP-AS | ART, DHA, AS |
15.3%, 15.3%, 15.7% |
Fe2+/Fe3+ | ART-CDT | in vitro | Guo et al., 2019 |
| 6 | DHA-MLPs | DHA | 82.1% | Fe2+/Fe3+ | ART-CDT | in vitro/in vivo | Li et al., 2019 |
| 7 | Fe3O4@SiO2-ART-HNPa | ART | 45.2% | Fe2+/Fe3+ | ART-CDT, PDT | in vitro | Qin et al., 2019 |
| 8 | A-TiO2-IONPs/ART | ART | 27.5% | Fe2+/Fe3+ | ART-CDT, PDT | in vitro/in vivo | Zhang et al., 2017 |
| 9 | HA-mFe3O4/ART | ART | 52.8% | Fe2+/Fe3+ | ART-CDT, AMF | in vitro/in vivo | Zhang et al., 2016 |
| 10 | cRGD-AFePt@NPs | ART | 5.2% | Fe2+/Fe3+ | ART-CDT Cisplatin |
in vitro | Gao et al., 2018 |
| 11 | Fe3O4@MnSiO3-FA | ART | 21.9% | Mn2+, Fe2+/Fe3+ | ART-CDT | in vitro/in vivo | Chen et al., 2015 |
| 12 | ART-MSP loaded with ICG |
ART | 22.5% | Fe2+/Fe3+ | ART-CDT, PTT | in vitro/in vivo | Ding et al., 2018 |
DLC, drug loading capacity; MNP, magnetic nanoparticle; MSP, porous magnetite supraparticles; AFM, alternating magnetic field (AMF) irradiation; ZFNPs, Zinc ferrite (ZnFe2O4) nanoparticles; HQ, 8-hydroxyquinoline; MLPs, magnetic nano-liposomes; HA, hyaluronic acid; ICG, indocyanine green; HNPa, 3-[1-hydroxyethyl]-3-devinyl-131-b,b-dicyanomethylene-131-deoxopyropheophorbide-a.